Tests CMS-D001 tablets in adults with moderate to severe plaque psoriasis
Tests CMS-D001 tablets against placebo in adults with moderate to severe plaque psoriasis.
Plain-language title generated from the registry record
Registry title: A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
Key facts
- Where
- Beijing, Bengbu, Changchun, Chengde, Guangzhou, Handan, Hangzhou, Harbin, Jinan, Jining, Nanyang, Sanmenxia, Shanghai, Shijiazhuang, Wuhu, Wuxi, and Zhengzhou, ChinaSee the 21 sites
- Phase
- Phase 2/3
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07432854, who can take part
Where in China
- Beijing Tongren Hospital affiliated to Capital Medical UniversityBeijing, ChinaNo longer taking part
- The First Affiliated Hospital of Bengbu Medical CollegeBengbu, ChinaNo longer taking part
- The First Hospital of Jilin UniversityChangchun, ChinaNo longer taking part
- Affiliated Hospital of Chengde Medical CollegeChengde, ChinaNo longer taking part
- Southern Medical University Dermatology HospitalGuangzhou, ChinaNo longer taking part
- Zhujiang Hospital of Southern Medical UniversityGuangzhou, ChinaNo longer taking part
- Affiliated Hospital of Hebei University of EngineeringHandan, ChinaNo longer taking part
- Hangzhou First People's HospitalHangzhou, ChinaNo longer taking part
- Hangzhou Third People's HospitalHangzhou, ChinaNo longer taking part
- Zhejiang Provincial People's HospitalHangzhou, ChinaNo longer taking part
- The Second Affiliated Hospital of Harbin Medical UniversityHarbin, ChinaNo longer taking part
- Shandong First Medical University Affiliated Dermatology HospitalJinan, ChinaNo longer taking part
- Jining First People's HospitalJining, ChinaNo longer taking part
- Nanyang Central HospitalNanyang, ChinaNo longer taking part
- Sanmenxia Central HospitalSanmenxia, ChinaNo longer taking part
- Shanghai Dermatology HospitalShanghai, ChinaNo longer taking part
- Shijiazhuang Traditional Chinese Medicine HospitalShijiazhuang, ChinaNo longer taking part
- The Fourth Affiliated Hospital of Hebei Medical UniversityShijiazhuang, ChinaNo longer taking part
- The First Affiliated Hospital of Wannan Medical College (Yijishan)Wuhu, ChinaNo longer taking part
- Wuxi Second People's HospitalWuxi, ChinaNo longer taking part
- Henan Provincial People's HospitalZhengzhou, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Dermavon Holdings Limited
- Trial code
- NCT07432854
- Record updated
- 25 February 2026
- Original description
This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.Read full original descriptionShow less
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ/Ⅲ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 Tablets in Adult Patients With Moderate to Severe Plaque Psoriasis
This study adopted a multicenter, randomized, double-blind, placebo-controlled phase II/III operation seamless adaptive design, aiming to evaluate the efficacy, safety and tolerability of CMS-D001 tablets in the treatment of patients with moderate to severe plaque psoriasis. The trial consists of two parts, including the Phase II clinical research stage and the Phase III clinical research stage.
Inclusion: Aged 18-75 years, willing to sign the ICF; Diagnosed with plaque psoriasis for at least 6 months prior to screening; At screening and baseline, PASI score ≥ 12 points, BSA ≥ 10%, sPGA ≥ 3; Be eligible for phototherapy or systemic therapy.
Exclusion: Non-plaque psoriasis (ie, guttate, pustular, erythrodermic, or inverse psoriasis) within 3 months prior to baseline; History of a serious bacterial, fungal, or viral infection requiring hospitalization or intravenous antimicrobial therapy within 3 months prior to the first dose; History of a bacterial, fungal, or viral infection requiring oral antimicrobial therapy within 4 weeks prior to the first dose; Active infection or acute illness within 7 days prior to the first dose. Chronic or recurrent infectious diseases at screening or baseline that, in the investigator's judgment, may increase safety risks; History of a major or unstable clinical condition within 6 months prior to the first dose, which would compromise participation; Previous or current autoimmune diseases; Allergic to any component of the investigational drug; Other skin diseases at screening or baseline Drug-induced psoriasis; History of severe herpes zoster or severe herpes simplex or current herpes simplex/zoster infection; Evidence of active TB. Patients with evidence of latent tuberculosis may enter the trial after sufficient treatment had initiated and maintained according to protocol; History of malignant tumour within 5 years before screening; Positive results of confirmatory test for hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis.